文献速递骨质疏松与钙磷/甲状旁腺

血液透析患者中甲状旁腺切除术与西那卡塞的比较

Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

这项前瞻性队列研究基于日本透析治疗学会肾脏数据登记,将2007年末全段甲状旁腺激素(PTH)≥300 pg/mL、2008至2009年接受甲状旁腺切除术(PTx)或起始西那卡塞治疗的患者按倾向评分1:3匹配。PTx组894例与西那卡塞组2682例比较6年内全因死亡风险,PTx与较低死亡风险相关(HR 0.78,95%CI 0.67-0.91,P=0.002),在PTH≥500 pg/mL及血钙≥10.0 mg/dL患者中更明显。

要点

  • PTx组6年死亡201例(22.5%),西那卡塞组736例(27.4%)。
  • PTx与西那卡塞相比全因死亡风险较低(HR 0.78,95%CI 0.67-0.91,P=0.002)。
  • PTH≥500 pg/mL及血钙≥10.0 mg/dL者中该关联更明显(交互P均<0.001)。

核心结论

  • 与西那卡塞相比,PTx与较低死亡风险相关,尤其在严重继发性甲状旁腺功能亢进患者中。

研究设计与样本

  • 前瞻性队列研究,纳入日本透析治疗学会肾脏数据登记中2007年末全段PTH≥300 pg/mL、2008至2009年接受PTx或起始西那卡塞治疗的患者,按倾向评分1:3匹配。
  • PTx组894例与西那卡塞组2682例 matched 后比较6年内全因死亡。

主要发现

  • 基线全段PTH中位数PTx组588 pg/mL,西那卡塞组566 pg/mL。
  • PTx较西那卡塞带来更大程度的全段PTH、钙和磷水平下降。
  • 6年随访期间PTx组201例(22.5%)死亡,西那卡塞组736例(27.4%)死亡。
  • PTx与西那卡塞相比全因死亡风险较低(HR 0.78,95%CI 0.67-0.91,P=0.002)。
  • 该关联在全段PTH≥500 pg/mL及血清钙≥10.0 mg/dL患者中更明显(交互P均<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Parathyroidectomy (PTx) and cinacalcet are both effective treatments for secondary hyperparathyroidism in hemodialysis patients, but limited data exist comparing the long-term outcomes of these interventions. OBJECTIVE: We aimed to compare the risk of mortality among hemodialysis patients who underwent PTx and those who started treatment with cinacalcet. METHODS: In this prospective cohort study, comprising patients from the Japanese Society for Dialysis Therapy Renal Data Registry, patients who had intact parathyroid hormone (PTH) levels ≥ 300 pg/mL in late 2007 and underwent PTx or started treatment with cinacalcet in 2008 to 2009 were matched by propensity score at 1:3. PTx and cinacalcet were compared for all-cause mortality within 6 years. RESULTS: Among eligible patients, 894 patients who underwent PTx were matched with 2682 patients who started treatment with cinacalcet. The median baseline intact PTH levels were 588 pg/mL and 566 pg/mL in the PTx and cinacalcet groups, respectively. PTx resulted in greater reductions in intact PTH, calcium, and phosphorus levels compared with cinacalcet. During the 6-year follow-up period, 201 patients (22.5%) in the PTx group and 736 patients (27.4%) in the cinacalcet group died. PTx was associated with a lower risk of mortality compared with cinacalcet (hazard ratio, 0.78 [95% CI, 0.67-0.91]; P = 0.002). This association was more pronounced in patients with intact PTH levels ≥ 500 pg/mL and in patients with serum calcium levels ≥ 10.0 mg/dL (both P for interaction < 0.001). CONCLUSION: PTx compared with cinacalcet is associated with a lower risk of mortality, particularly among patients with severe secondary hyperparathyroidism.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Komaba H, Hamano T, Fujii N, et al. Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis. J Clin Endocrinol Metab. 2022. PMID: 35277957. doi:10.1210/clinem/dgac142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。